Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects.
about
Ribosome display and selection of human anti-cD22 scFvs derived from an acute lymphocytic leukemia patient.Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.The Expression and Prognostic Impact of CD95 Death Receptor and CD20, CD34 and CD44 Differentiation Markers in Pediatric Acute Lymphoblastic LeukemiaEmerging drugs for adult acute lymphoblastic leukaemia.Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodiesFavorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remissionSafety of conditioning agents for allogeneic haematopoietic transplantation.Expression of CD20 in B Cell Precursor Acute Lymphoblastic Leukemia.Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies.Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia.BAALC-associated gene expression profiles define IGFBP7 as a novel molecular marker in acute leukemia.Who Should Receive a Transplant for Acute Lymphoblastic Leukaemia?A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies.Molecular diagnostics, targeted therapy, and the indication for allogeneic stem cell transplantation in acute lymphoblastic leukemia.A naturally processed HLA-DR-bound peptide from the IL-9 receptor alpha of HTLV-1-transformed T cells serves as a T helper epitope.Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia.Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia.Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy.
P2860
Q33316826-535D8646-FC9B-425A-9EF2-6DC90E90EA83Q33632278-9AC28776-E258-4B01-B874-3AB7DBFC69F4Q34980316-A688A38F-B6F3-4F7F-B783-D664841EFF5AQ35118521-8E993A1C-21CA-4161-B345-6939F92DE29AQ36219661-203DEF60-12CD-4D14-A8FB-E5E70F498A2EQ37340948-7669703F-2DC5-4150-96C5-87CA1B4540C0Q37369934-D5EE1B96-D2E6-4FB8-AC07-E7744B76C1AEQ37510948-0B38857A-27DA-44E5-8185-D83B13328221Q37578185-4179A5A4-0FE7-4F45-A8BE-079E4BFC58D5Q38094099-6C4EDB9A-66B5-4BFD-83AE-1FE9B9254FABQ38224988-AF62FB11-6C54-495E-8BD5-C9D0631F2D6AQ38343448-27B51231-2A9B-41C3-A920-10812EDE85DEQ38953608-4E82C0E5-47EF-4189-8A05-62986D2E7795Q39004366-1D9C7A20-382F-462F-B1AB-F9BB20E6E84AQ39112294-5280D681-9D6B-4AC6-BD7C-36ACFA73715FQ39341283-86F4FB4F-D7DB-416E-9AA3-C19523F86FAAQ40208212-B7E4032B-A6B9-4B1E-BBC1-AB28B43146FEQ42616476-5DB8103C-BC2D-4E43-9754-DAD47D6D15CDQ44258556-B6B89542-163C-4000-BC97-EE692A4DACAC
P2860
Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Treatment with monoclonal anti ...... nowledge and future prospects.
@ast
Treatment with monoclonal anti ...... nowledge and future prospects.
@en
type
label
Treatment with monoclonal anti ...... nowledge and future prospects.
@ast
Treatment with monoclonal anti ...... nowledge and future prospects.
@en
prefLabel
Treatment with monoclonal anti ...... nowledge and future prospects.
@ast
Treatment with monoclonal anti ...... nowledge and future prospects.
@en
P1433
P1476
Treatment with monoclonal anti ...... nowledge and future prospects.
@en
P2093
Dieter Hoelzer
Nicola Gökbuget
P304
P356
10.1007/S00277-003-0752-8
P577
2003-11-26T00:00:00Z